OHSU
 

IRB #

IRB00010264

Title

Protocol H8A-MC-LZAZ(a)/ADC-040-A4 Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4 Study)

Principal Investigator

Deniz Erten-Lyons

Study Purpose

The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid.

Medical Condition(s)

Alzheimer's disease

Eligibility Criteria

In good general health, 65-85 years old, at risk for memory decline due to amyloid in the brain.

Healthy Volunteers Needed

Yes

Placebo Chance

50

Duration of Participation

168 weeks

Minors Included

No

Contact

Lisa Loree 503-494-7615

Sponsor

National Institute on Aging, Alzheimer's Disease Cooperative Studies, Eli Lilly and Co.

Recruitment End

12/01/2015

Compensation Provided

Yes

Compensation

$25.00 for each completed clinical study visit and $25.00 for each completed infusion visit.


Go Back